Benzinga | Oct 29, 2021 08:19AM EDT

Chardan Capital Maintains Buy on Alnylam Pharmaceuticals, Raises Price Target to $200

Chardan Capital analyst Keay Nakae maintains Alnylam Pharmaceuticals (NASDAQ:ALNY) with a Buy and raises the price target from $190 to $200.